An assessment of clinical outcomes of medication abortion without pretreatment ultrasonography in Planned Parenthood, United States, 2020-2021

被引:2
作者
Simons, Hannah R. [1 ,2 ]
Diemert, Sarah [1 ,2 ]
Passman, Rebecca [1 ,2 ]
Dean, Gillian [1 ,2 ]
机构
[1] Planned Parenthood Federat Amer, Res & Evaluat Dept, New York, NY 10038 USA
[2] Planned Parenthood Federat Amer, Med Serv Dept, New York, NY 10038 USA
关键词
Abortion; Medication abortion; Mifepristone; Pregnancy; Ultrasonography; TO-PATIENT TELEMEDICINE; MIFEPRISTONE; MISOPROSTOL;
D O I
10.1016/j.contraception.2024.110469
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: Routine ultrasound before medication abortion (MAB) may create an impediment to expanding abortion access. This study examines clinical outcomes of MAB without pretreatment ultrasound evaluation at Planned Parenthood health centers in multiple states. Study design: We conducted a secondary analysis of data from 23 US -based Planned Parenthood affiliates that provided MAB without pretreatment ultrasound for eligible patients from March 2020 to December 2021. Affiliates aggregated electronic health record data from MABs at <= 77 days gestation (based on selfreport of last menstrual period) without a pretreatment ultrasound ( N = 18,041). Among MABs with known outcomes ( N = 9821), we calculated the incidence rates and 95% confidence intervals (CI) for completed abortion, ongoing pregnancy, subsequent procedure, emergency department/hospital visits associated with MAB, ectopic pregnancies, and gestational duration greater than 77 days. Results: Among MABs with known outcomes, 96.3% had a complete abortion (95% CI = 95.9%-96.7%), and 2.0% had an ongoing pregnancy (95% CI = 1.7%-2.3%). Four percent had a subsequent procedure (95% CI = 3.6%-4.4%), and 2.3% had a documented emergency department/hospital visit (95% CI = 2.0%-2.6%). Less than 1% had a confirmed ectopic pregnancy (0.15%, 95% CI = 0.09%-0.25%) and had a gestational duration later identified to be greater than 77 days (0.13%, 95% CI = 0.05%-0.29%). Conclusions: Our calculated incidence rates of clinical outcomes align with rates from the previous literature on MAB and from the emerging literature on MAB without pretreatment ultrasonography. Findings from this analysis suggest that MAB without pretreatment ultrasound is safe and effective for eligible patients. Implications: This large US study found that medication abortion without pretreatment ultrasonography results in similar clinical outcomes to prepandemic models that include pretreatment ultrasonography. Medication abortion without a pretreatment ultrasound may be adopted by abortion providers seeking to expand options for their patients as access to abortion continues to erode. (c) 2024 Elsevier Inc. All rights reserved.
引用
收藏
页数:6
相关论文
共 20 条
  • [1] Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study
    Aiken, A. R. A.
    Lohr, P. A.
    Lord, J.
    Ghosh, N.
    Starling, J.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (09) : 1464 - 1474
  • [2] Clinical and service delivery implications of omitting ultrasound b efore me dication abortion provide d via direct-to-patient telemedicine and mail in the U.S
    Anger, Holly A.
    Raymond, Elizabeth G.
    Grant, Melissa
    Haskell, Sue
    Boraas, Christy
    Tocce, Kristina
    Banks, Joey
    Coplon, Leah
    Shochet, Tara
    Platais, Ingrida
    Winikoff, Beverly
    [J]. CONTRACEPTION, 2021, 104 (06) : 659 - 665
  • [3] [Anonymous], 2016, MIFEPREX (mifepristone) tablets, for oral use 2016
  • [4] Centers for Disease Control and Prevention, Current trends ectopic pregnancy - United States, 1990-1992
  • [5] Mifepristone With Buccal Misoprostol for Medical Abortion A Systematic Review
    Chen, Melissa J.
    Creinin, Mitchell D.
    [J]. OBSTETRICS AND GYNECOLOGY, 2015, 126 (01) : 12 - 21
  • [6] Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research
    Clark, Wesley H.
    Gold, Maiji
    Grossman, Daniel
    Winikoff, Beverly
    [J]. CONTRACEPTION, 2007, 75 (04) : 245 - 250
  • [7] Medical management of first-trimester abortion
    Creinin, Mitchell D.
    Grossman, Daniel A.
    [J]. CONTRACEPTION, 2014, 89 (03) : 148 - 161
  • [8] New technologies permit safe abortion at less than six weeks' gestation and provide timely detection of ectopic gestation
    Edwards, J
    Carson, SA
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 176 (05) : 1101 - 1106
  • [9] Telemedicine for medical abortion: a systematic review
    Endler, M.
    Lavelanet, A.
    Cleeve, A.
    Ganatra, B.
    Gomperts, R.
    Gemzell-Danielsson, K.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 (09) : 1094 - 1102
  • [10] Food and Drug Administration, MIFEPREX (mifepristone) tablets label